To test their hypothesis, they used an inhibitor of the M-CSF receptor (PLX3397) in their original mouse model of TLE. Fascinatingly, treating the TLE mice with PLX3397 both rescued the expression of the genes altered in TLE and limited seizure frequency. To confirm that this wasn’t an idiosyncratic result, they then validated their results in another mouse model of TLE (intrahippocampal kainate) and obtained similar seizure-reducing results. These results raise the possibility of a novel disease-modifying treatment for TLE as well as a new paradigm for finding additional antiepileptic drugs.